Leadership Crisis Erupts at Biotech Firm Physiomics

Major shareholder Michael Whitlow demands removal of all four directors at UK biotech Physiomics, triggering a defensive response from management and a potential shareholder vote.

A significant shareholder has launched an aggressive campaign to oust the entire board of directors at UK-based biotechnology services provider Physiomics. The move has triggered a defensive response from the incumbent management, setting the stage for a pivotal battle over corporate control.

Activist Investor Demands Sweeping Board Changes

The challenge comes from Michael Whitlow, who holds approximately 13.68% of the company's shares. Whitlow has formally requested the convening of an extraordinary general meeting. His proposal is unequivocal: the removal of all four sitting directors, including Dr. Jim Millen and Dr. Tim Corn.

In their place, Whitlow has nominated a slate of four new candidates for the board. The proposed new leadership team consists of himself, Nicholas Tulloch, Ian Bagnall, and Martin Gouldstone. The removal of the current directors is conditional on the successful appointment of at least two of these nominees.

Management Resists as Legal Review Begins

The existing Physiomics board has reacted with concern to the shareholder's demands. In an initial statement, the directors argued that a complete overhaul of the company's leadership would be "highly damaging" to both the business and its shareholders. The company's legal advisors are now examining whether the request complies with the formal requirements of UK company law.

Should the demand be deemed valid, a strict timeline will be initiated:
* The company must issue the notice for the general meeting by April 3, 2026.
* The meeting itself would then need to be held within 28 days of that notice.

This confrontation highlights the growing influence of activist investors within the UK's small-cap market. For Physiomics, a firm specializing in mathematical modeling for drug development and personalized medicine, the clash puts strategic continuity at risk. In such a specialized field, stability in leadership is often viewed as a critical factor in maintaining trust with clients and partners.

A decision regarding the legal validity of the shareholder's request is anticipated in the coming days. If the matter proceeds to a vote, the future strategic direction of Physiomics will be decided by its shareholders, who must choose between the established management and the new course proposed by Whitlow.